Malta - enska - Medicines Authority

sanofi malta limited - dimeticone; aluminium hydroxide; magnesium hydroxide - chewable tablet - dimeticone 25 mg; aluminium hydroxide 200 mg; magnesium hydroxide 200 mg - drugs for acid related disorders

Malta - enska - Medicines Authority

sanofi malta limited - dimeticone; aluminium hydroxide; magnesium hydroxide - oral suspension - dimeticone 25 mg; aluminium hydroxide 114 mg; magnesium hydroxide 200 mg - drugs for acid related disorders

Malta - enska - Medicines Authority

opella healthcare france sas t/a sanofi 157 avenue charles de gaulle, 92200 neuilly-sur-seine , france - dimeticone, aluminium oxide, hydrated, magnesium hydroxide - chewable tablet - dimeticone 25 mg aluminium oxide, hydrated 200 mg magnesium hydroxide 200 mg - drugs for acid related disorders

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

derma uk ltd - dimeticone 1000; cetrimide - cutaneous cream - 100mg/1gram ; 3mg/1gram

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

3m australia pty ltd - ethanol absolute, quantity: 61 % w/w - lotion - excipient ingredients: glycerol; macrogol 900; c20-40 pareth-24; behenyl alcohol; dimeticone 350; macrogol 600; cetyl palmitate; squalane; beheneth-10; purified water - healthcare professional antiseptic hand rub

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - estradiol, quantity: 0.585 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; ethylene/vinyl acetate copolymer; 1,1-dichloroethylene, chloroethylene polymer; polyethylene; sodium carbonate; polyethylene terephthalate; polyvinylidene flouride - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

beiersdorf australia ltd - homosalate, quantity: 90 mg/g; octocrylene, quantity: 45 mg/g; octyl salicylate, quantity: 45 mg/g; phenylbenzimidazole sulfonic acid, quantity: 25 mg/g; butyl methoxydibenzoylmethane, quantity: 45 mg/g - cream - excipient ingredients: sodium stearoyl glutamate; sodium hydroxide; ethylhexylglycerin; phenoxyethanol; glycerol; xanthan gum; dl-alpha-tocopheryl acetate; methylpropanediol; purified water; octyl stearate; behenyl alcohol; ammonium acryloyldimethyltaurate/vp copolymer; magnolia officinalis; trisodium edetate; cetostearyl alcohol; dimeticone 6; tapioca starch; acrylates/c10-30 alkyl acrylate crosspolymer; nelumbo nucifera flower wax; fragrance (perfume) - spf 30 broad spectrum high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen)

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 420 mg (equivalent: lipase, qty 35000 ph eur unit; equivalent: amylase, qty 25200 ph eur unit; equivalent: protease, qty 1400 ph eur unit) - capsule - excipient ingredients: macrogol 4000; hypromellose phthalate; cetyl alcohol; triethyl citrate; dimeticone 1000; gelatin; iron oxide red; iron oxide yellow; iron oxide black; titanium dioxide; sodium lauryl sulfate - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: ? cystic fibrosis ? chronic pancreatitis ? pancreatic surgery ? gastrointestinal bypass surgery (e.g. bilroth ii gastroenterostomy) ? ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

viatris limited - pancreatin 420mg (amylase 25,200 ph eur u, lipase 35,000 ph eur u, protease 1,400 ph eur u.); pancreatin 420mg (amylase 25,200 ph eur u, lipase 35,000 ph eur u, protease 1,400 ph eur u.) - modified release capsule - 420 mg - active: pancreatin 420mg (amylase 25,200 ph eur u, lipase 35,000 ph eur u, protease 1,400 ph eur u.) excipient: cetyl alcohol dimeticone gelatin hypromellose phthalate iron oxide black iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate titanium dioxide triethyl citrate active: pancreatin 420mg (amylase 25,200 ph eur u, lipase 35,000 ph eur u, protease 1,400 ph eur u.) excipient: cetyl alcohol dimeticone gelatin hypromellose phthalate iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate triethyl citrate - creon is indicated for the treatment of pancreatic exocrine insufficiency (pei) in paediatric and adult patients. pancreatic exocrine insufficiency is often associated with, but not limited to: · cystic fibrosis · chronic pancreatitis · post-pancreatectomy · post-gastrointestinal bypass surgery ,(e.g. billroth ii, gastroenterostomy) · ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 0.585 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.